Iridium Network Invests in RayCare to Become Its Leading Oncology Information System


STOCKHOLM, October 29, 2021 /PRNewswire/ — Iridium Network has been instrumental in the development of RayCare and in February 2018 it became the first hospital in the world to clinically use RayCare, just two months after the system was released. Currently, RayStation®* and RayCare are clinically implemented in the treatment of all Stereotactic Body Radiation Therapy (SBRT) as well as Radiosurgery (SRS) treatments. Now the goal is to further streamline the workflow so that they can eventually manage all clinical activities, for all cancer types and in all their clinics, with RayCare. Achieving this level of standardization and automation represents a significant milestone in the partnership between RaySearch and Iridium Network and in healthcare for the greater Antwerp Region.

RaySearch and Iridium Network also collaborate closely on machine learning, creating and validating segmentation and planning models. This project has been very successful and will be further extended in the coming years towards an increased level of automation with machine learning for the majority of treatment sites.

Teacher. dr. Dirk VerellenIridium Network, states: “The clinical workflow in radiation oncology is becoming increasingly complex with the introduction of personalized and adaptive treatments. Standardization and automation are key to ensuring patient safety and quality assurance in this fast-paced and ever-changing environment. ideal partner to coordinate and monitor our clinical care pathways across the network and provide access to state-of-the-art radiation oncology for every patient in the greater Antwerp.”

Teacher. Dr. Piet Dirix, Iridium Network, says: “Cancer cases are expected to increase by 2030, with an expected increase of at least 30% in new diagnoses worldwide. As up to two-thirds of all cancer patients require radiotherapy during their illness, we are preparing to treat many more patients without necessarily having more resources. Our clinical experience with RayStation and RayCare has taught us that we can treat our patients more safely, more accurately and more efficiently with these systems working in tandem. , we believe we can treat our growing number of patients with our current resources with these smart software innovations.”

Johan Löf, Founder and CEO of RaySearch, said, “This long-term commitment from Iridium Network demonstrates its confidence in RayCare as an innovative oncology information system contributing to safe and effective cancer care. The clinical expertise and high commitment of Iridium Network has been instrumental in the development of RayCare, and we look forward to reaching the milestone of connecting RayCare to Varian TrueBeam®** linacs at Iridium. »

About the Iridium Network

Iridium is a highly specialized radio-oncology network for the 3 hospital networks (MIRA, HELIX and GZA/ZNA) in the greater region of Antwerp, representing 18 hospital sites. Created in 2006, Iridium Network is today the largest radiotherapy network Belgium and a leading center of expertise of international renown. At the end of 2021, the milestone of 6,000 annual treatments will be exceeded. The head office is located on the campus of the GZA Sint-Augustinus hospitals in Wilrijk.

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions to improve cancer treatment. RaySearch markets the RayStation® treatment planning system (TPS) and the RayCare® oncology information system (OIS). The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®. RayIntelligence is an oncology analytics system (OAS) that enables cancer clinics to collect, structure and analyze data. RayCommand®, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch software is used by over 2,600 clinics in over 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in stockholm and the stock has been listed on Nasdaq Stockholm since 2003.

About RayStation

RayStation® is a flexible and innovative treatment planning system chosen by many leading cancer centers around the world. It combines unique features such as unparalleled adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for optimizing treatment plans for HDR brachytherapy and external beam therapy with photons, electrons and protons , as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing a control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also integrates seamlessly with RayCare. By harmonizing treatment planning, we enable better care for cancer patients worldwide.

About RayCare

The RayCare® Oncology Information System (OIS) is designed to support the many complex logistical challenges facing oncology clinics today. RayCare is tightly integrated with RayStation® and provides seamless access to all the powerful planning tools of RayStation and RayCommand®. The system efficiently coordinates radiation therapy activities and offers advanced features for clinical workflow automation and adaptive radiation therapy. RayCare answers clinics’ demand for a more user-friendly, workflow-oriented information system that can support the future of cancer care.

* Subject to regulatory approval in certain markets.
** Varian and TrueBeam trademarks are registered trademarks of Varian Medical Systems Inc.

More information about RaySearch is available at


For more information please contact:

Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
[email protected]

Peter ThysellChief Financial Officer, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
[email protected]

This information was brought to you by Cision,c3443541

The following files are available for download:

SOURCE RaySearch Laboratories


About Author

Comments are closed.